© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Metagenomi, Inc. Common Stock (MGX) stock surged +2.06%, trading at $1.24 on NASDAQ, up from the previous close of $1.22. The stock opened at $1.22, fluctuating between $1.21 and $1.24 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 06, 2026 | 1.22 | 1.24 | 1.21 | 1.24 | 145.6K |
| Aug 05, 2026 | 1.22 | 1.23 | 1.20 | 1.22 | 77.22K |
| Aug 04, 2026 | 1.20 | 1.23 | 1.20 | 1.21 | 110.95K |
| Aug 03, 2026 | 1.19 | 1.24 | 1.19 | 1.21 | 134.02K |
| Jul 31, 2026 | 1.21 | 1.22 | 1.19 | 1.19 | 135.77K |
| Jul 30, 2026 | 1.20 | 1.23 | 1.20 | 1.22 | 132.7K |
| Jul 29, 2026 | 1.21 | 1.22 | 1.20 | 1.21 | 35.41K |
| Jul 28, 2026 | 1.21 | 1.23 | 1.20 | 1.21 | 109.07K |
| Jul 27, 2026 | 1.21 | 1.24 | 1.20 | 1.21 | 68.24K |
| Jul 24, 2026 | 1.24 | 1.24 | 1.20 | 1.21 | 64.4K |
| Jul 23, 2026 | 1.23 | 1.23 | 1.21 | 1.22 | 51.21K |
| Jul 22, 2026 | 1.30 | 1.30 | 1.20 | 1.24 | 534.18K |
| Jul 21, 2026 | 1.22 | 1.24 | 1.20 | 1.22 | 189.11K |
| Jul 20, 2026 | 1.24 | 1.26 | 1.20 | 1.22 | 170.42K |
| Jul 17, 2026 | 1.25 | 1.26 | 1.22 | 1.24 | 127.33K |
| Jul 16, 2026 | 1.29 | 1.29 | 1.23 | 1.24 | 163.85K |
| Jul 15, 2026 | 1.32 | 1.34 | 1.29 | 1.29 | 124.56K |
| Jul 14, 2026 | 1.32 | 1.37 | 1.31 | 1.32 | 225.16K |
| Jul 13, 2026 | 1.29 | 1.34 | 1.26 | 1.32 | 372.44K |
| Jul 10, 2026 | 1.26 | 1.31 | 1.22 | 1.27 | 349.21K |
Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.
| Employees | 118 |
| Beta | 0.7 |
| Sales or Revenue | N/A |
| 5Y Sales Change% | 28.145% |
| Fiscal Year Ends | N/A |
| Sector | Healthcare |
| Industry | Biotechnology |